American Society of Hematology

ASH is the leader in representing the interests of scientists and clinicians working in the field of hematology on Capitol Hill and within federal agencies concerned with the study and treatment of blood-related diseases.

  • Urge Your Senators and Representative to Support the Cancer Treatment Parity Act

    Legislation will soon be reintroduced in the U.S. House of Representatives and U.S. Senate that would ensure that patients enrolled in certain federally regulated health plans have access and insurance coverage for all anti-cancer regimens.

  • Take Action to Support Funding for Medical Research

    Your Senators and Representative need to continue to hear from you about the impact that unpredictable funding and potential funding cuts will have on your research and the patients you treat and the need for them to recognize the value of biomedical research by investing in the NIH.

View all action alerts
  • NIH Seeks Information on Optimizing Funding Policies and Other Strategies to Improve the Impact and Sustainability of Biomedical Research

    The NIH has released a request for information soliciting input on the possible development of new policies and strategies to improve the impact and sustainability of its funded biomedical research enterprise.  ASH members are encouraged to submit comments in response to this request.

  • CMS Issues Guidance on Biosimilar Reimbursement and Formulary Policy

    On March 30, the Centers for Medicare & Medicaid Services (CMS) issued two documents on Medicare Part B and Part D payment for biosimilars that are relevant to hematology.  On March 6, 2015, the FDA)approved filgrastim-sndz (ZARXIO Injection, Sandoz Inc.), as a biosimilar to U.S.-licensed Neupogen, which is important to hematologic therapy.  Some of the most important regimens for the treatment of patients with hematologic disorders are biologic, so the release of this information is helpful for the field.

  • IOM National Cancer Policy Forum Releases a Report on Policy Issues in the Development and Adoption of Biomarkers for Molecularly Targeted Cancer Therapies

    The Institute of Medicine National Cancer Policy Forum (IOM NCPF) has released a summary report on a workshop it hosted on November 10, 2014, titled "Policy Issues in the Development and Adoption of Biomarkers for Molecularly Targeted Cancer Therapies."  This report highlights the numerous challenges raised by workshop participants on the development of biomarker tests, implementation of cancer therapies into the clinic, clinical trial structure and reimbursement issues related to molecular profiling tests.

  • New SGR Bill Released

    On March 19, the House of Representatives introduced a bill that would permanently address the SGR issue.  This bill largely follows the policy of the bill that was introduced by the committees of jurisdiction during the last Congress.  That bill, which ASH supported, eliminated the SGR update formula in favor of a new payment schedule.  Follow the link above to read more about the bill.

View all policy news
back to top